QR-504a
- Generic Name
- QR-504a
Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
Phase 1
Withdrawn
- Conditions
- Fuchs Endothelial Corneal DystrophyLRSFECD3Corneal DiseasesDescemet's Membrane Disorder
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- ProQR Therapeutics
- Registration Number
- NCT05052554
- Locations
- 🇬🇧
Moorfields Eye Hospital, NIHR Clinical Research Facility, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath